21.18
+0.71%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About vTv Therapeutics
From its filings with the US Securities and Exchange Commission
vTv Therapeutics is based in High Point, North Carolina and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker VTVT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $27.0m. At that date it held total assets of $89.9m and shareholders' equity of $64.4m.
We are a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases with the goal of improving patient outcomes. Our lead product candidate, cadisegliatin (TTP399), is a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated in a Phase 3 clinical trial as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). The Cadisegliatin as Adjunctive Therapy to Insulin in Participants with Type 1 Diabetes ("CATT1") Phase 3 clinical trial is a randomized, double-blind, placebo-controlled trial designed to evaluate the effect of cadisegliatin on hypoglycemia outcomes in patients with T1D. The primary endpoint is the reduction in the frequency of Level 2 hypoglycemia (blood glucose <54 mg/dL) and Level 3 (severe) hypoglycemia over a six-month treatment period. A key secondary endpoint is change in hemoglobin A1c (HbA1c), a standard measure of glycemic control, to assess cadisegliatin’s potential to reduce hyperglycemia. The CATT1 trial will randomize 150 patients with T1D on a 1:1:1 basis (50 patients per study arm) to receive 800 mg cadisegliatin daily, 800 mg cadisegliatin twice daily, or placebo.
Quoted from its 10-K, filed 10 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Jul 2015
- Employees
- 26
- Website
- vtvtherapeutics.com ↗
- Head office
- 3980 PREMIER DR, HIGH POINT, NC, 27265
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Paul SekhriChairman of the Board, President, Chief Executive Officer, since 2022$3.9m
- Dr. Michael TungExecutive Vice President, Chief Financial Officer
- Mr. Richard NelsonExecutive Vice President - Corporate Development, Director, since 2020$514,071
- Mr. Daniel SpiegelmanDirector$121,079
- Dr. Srinivas AkkarajuIndependent Director$141,518
- Mr. Fahed Al MarzooqiIndependent Director$142,091
- Dr. Raymond CheongIndependent Director$153,340
- Dr. Anne PhillipsIndependent Director$142,103
- Mr. Burns McclellanInvestor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 35
- Environment
- 34
- Social
- 55
- Governance
- 14
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Clinical-stage biopharmaceutical company with 26 employees focused on oral small molecule drug development.
- Azeliragon (TTP488) in Phase III for Alzheimer's disease targeting RAGE receptor.
- TTP399 completed Phase IIb for type II diabetes as liver-selective glucokinase activator.
Weaknesses
- Limited workforce of 26 employees in clinical-stage biopharmaceutical sector.
- IPO listing date 30 July 2015 may indicate early-stage financial constraints.
- High Point, North Carolina headquarters location lacks major biotech cluster presence.
Opportunities
- Phase III enrollment for azeliragon (TTP488) could lead to Alzheimer's disease treatment approval.
- TTP273 in Phase II for diabetes targeting GLP-1r offers potential market expansion.
- Additional three programs in clinical development may yield new drug approvals.
Threats
- Alzheimer's disease drug candidate azeliragon (TTP488) faces competition in Phase III trials.
- Type II diabetes drug TTP399 faces regulatory hurdles in Phase IIb completion.
- Biotechnology sector competition intensifies with multiple clinical-stage companies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.